Key facts
- It has raised $9.2M; the latest was Accelerator/Incubator in Jul 2025.
- Notable investors include A&E Investments, MSD Global Health Innovation Fund, Lip-Bu Tan, Life Sciences BC, Accellius Capital — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Variational AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Variational AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Variational AI
Developer of an artificial intelligence-based drug discovery platform designed to accelerate preclinical research and develop novel kinase inhibitors for solid tumors. The company offers a foundation model that designs potent, selective, safe, and synthesizable small molecules, degraders, and payloads for ADCs, enabling biopharmaceutical companies to perform efficient multi-property molecular optimization, identify new therapeutic candidates across diverse targets, and reduce the time required for drug discovery.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2019
- Employees
- 20
- Website
- variational.ai/
- Ownership
- Privately Held (backing)
Variational AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Variational AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Variational AI in its N-PORT filings yet. We sweep new filings monthly.